



Aarey

DRUGS & PHARMACEUTICALS.LTD.

**MANUFACTURERS OF BULK DRUGS &
DEALERS OF CHEMICALS & SOLVENTS**

CIN No.: L99999MH1990PLC056538

H. O. : 107,204, SAHAKAR BHAVAN, 340 / 48, N. N. STREET, MASJID BUNDER, MUMBAI - 400 009. ☎ : (022) 66312997 / 98 / 99 Fax : 66313166 E-mail : info@aareydrugs.com
REGD. OFFICE & FACTORY : E - 34, M.I.D.C., TARAPUR, BOISAR, DIST.: PALGHAR - 401 506. ☎ : (02525) 652165 E-mail : works@aareydrugs.com Web : www.aareydrugs.com

14th August'2019

To,
Dept. of Corporate Services
The Bombay Stock Exchange Ltd
1st floor, Rotunda Building,
M.S.Marg, Mumbai-400 001.

**Sub : UN-AUDITED QUARTERLY RESULT (CLAUSE 41) FOR THE
QUARTER ENDED 30th June'2019**

Dear Sir,

Pursuant to listing agreement we are enclosing herewith the Un-audited financial results for the quarter ended 30th June'2019 with limited review report of the auditors.

Kindly acknowledge the same & oblige.

Thanking You,

Yours faithfully,

For Aarey Drugs & Pharmaceuticals Ltd

Authorised Signatory
Encl.: a/a



H. O. : 107,204, SAHAKAR BHAVAN, 340 / 48, N. N. STREET, MASJID BUNDER, MUMBAI - 400 009. ☎ : (022) 66312997 / 98 / 99 Fax : 66313166 E-mail : info@aareydrugs.com
REGD. OFFICE & FACTORY : E - 34, M.I.D.C., TARAPUR, BOISAR, DIST.: PALGHAR - 401 506. ☎ : (02525) 652165 E-mail : works@aareydrugs.com Web : www.aareydrugs.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE, 2019				
Particulars	(Rs. In Lakhs)			
	3 months ended on 30.06.2019	3 months ended on 31.03.2019	3 months ended on 30.06.2018	Previous year ended on 31.03.2019
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
Revenue from Operations	6,620.31	13,731.14	6,735.73	35,474.14
Other Income	150.90	182.03	124.78	433.83
TOTAL INCOME	6,771.21	13,913.17	6,860.51	35,907.97
EXPENSES				
Cost of Materials Consumed	6,350.61	13,225.11	6,534.50	34,097.28
Changes in inventories	-	-	-	-
Excise Duty on Sale of Goods	-	-	-	-
General Administrative Expense	105.27	148.62	57.90	336.98
Selling and Distribution Exp	38.04	109.49	23.51	251.28
Depreciation and Amortization Expense	25.10	46.28	17.80	100.83
Finance Cost	42.28	65.69	16.67	222.99
Other Expenses	-	-	-	-
TOTAL EXPENSES	6,561.30	13,595.19	6,650.38	35,009.37
Profit Before Exceptional Items and Tax	209.91	317.98	210.13	898.60
Exceptional Items				
Profit Before Tax				
Tax Expenses				
a) Current Tax	-	(225.00)	-	(225.00)
b) Deferred Tax	-	(19.42)	-	(19.42)
Profit for the year	209.91	73.56	210.13	654.18
Other Comprehensive Income				
Items that will not be reclassified subsequently to Profit or Loss	-	-	-	-
a) Items that will not be classified to profit and loss	-	-	-	-
b) Income tax relating to Items that will not be reclassified to Profit or loss	-	-	-	-
Total Comprehensive Income for the year	209.91	73.56	210.13	654.18
Earnings Per Share				
a) Basic EPS (Rs.)	0.90	0.31	0.90	2.80
b) Diluted EPS (Rs.)	0.90	0.31	0.90	2.80
Number of Shares	2,33,84,684	2,33,84,684	2,33,84,684	2,33,84,684
Percentage of Shareholding	100.00%	100.00%	100.00%	100.00%

Notes :

- The above results are restated as per the applicable Indian Accounting Standard (Ind AS) and are approved by audit committee and taken on record by the Board of Directors at their meeting held on 14th August, 2019
- Status of Investor Complaints (Nos): Opening Balance as on 01.04.2019 - 1 ; Received During the Quarter - 2 ; Disposed Off During the Quarter - 3 ; Closing Balance as on 30.06.2019 - Nil.
- The Figures of the previous year/period have been regrouped wherever necessary.

Place: Tarapur

Date: 14th August,2019

By Order of the Board of Directors

Mihir R. Shatalia

Managing Director





LIMITED REVIEW REPORT

**TO,
THE BOARD OF DIRECTORS,
AAREY DRUGS & PHARMACEUTICALS LIMITED**

We have reviewed the accompanying statement of unaudited financial results of **Aarey Drugs & Pharmaceuticals Limited** for the quarter ended June 30th, 2019, being submitted by the Company in pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, as modified by Circular No. "CIR/CFD/FAC/62/2016" dated July 05, 2016.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards, prescribed under section 133 of the Companies Act 2013 read with relevant rules issued there under and accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review Conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards and accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. "CIR/CFD/FAC/62/2016" dated July 05, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For DMKH & Co.
Chartered Accountants
FRN 116886W

Manish Kankani

Manish Kankani

Partner

M.No. 158020

UDIN: 19158020AAAAGR3025

Mumbai

Date: 14th August, 2019



Reconciliation of Net Profit as per IND AS and IGAAP
(Rs. in Lakhs)

S.No.	Particulars	Quarter Ended		Year Ended
		30-June-2019	31-Mar-2019	31-Mar-2019
1	Net Profit/(loss) after tax for the period as per IGAAP	209.91	92.8	673.60
2	Impact of IND AS on comprehensive Income	-	(19.42)	(19.42)
3	Impact of IND AS on other comprehensive Income	-	-	-
4	Total comprehensive income for the period as per IND AS	209.91	73.56	654.18

Place: Mumbai


Date: 13th August , 2019



Certificate of Managing Director (MD)

I, Mihir R Ghatalia, Managing Director (MD) of Aarey Drugs & Pharmaceuticals Ltd.,
certify;

- 1) That I have reviewed the Unaudited Financial Statements for the quarter ended 30th June, 2019 and to the best of my knowledge and belief:
 - a) These financial results do not contain any materially untrue statement or omit any material fact nor contain statement that might be misleading, and
 - b) These financial statements present a true and fair view of the Company's affairs and are in compliance with the applicable laws and regulations.
- 2) That there are to the best of my knowledge and belief, no transactions entered into by the company during the quarter, which are fraudulent, illegal or violative of the Company's Code of Conduct.
- 3) That I accept responsibility for establishing and maintaining internal controls, I have evaluated the effectiveness of the internal control systems of the Company and I have disclosed to the auditors and the Audit Committee, deficiencies in the design or operation of internal controls, if any, of which I am aware and the steps that I have taken to rectify the identified deficiencies.


Mihir R Ghatalia
MD
Date: 14/08/2019
Place: Mumbai

Certificate of Cheif Financial Officer (CFO)

I, Rajesh P Ghatalia, Cheif Financial Officer (CFO) of Aarey Drugs & Pharmaceuticals Ltd., certify;

1. That I have reviewed the Unaudited Financial Statements for the quarter ended 30th June, 2019 and to the best of my knowledge and belief:
 - a) These financial results do not contain any materially untrue statement or omit any material fact nor contain statement that might be misleading, and
 - b) These financial statements present a true and fair view of the Company's affairs and are in compliance with the applicable laws and regulations.
- 2) That there are to the best of my knowledge and belief, no transactions entered into by the company during the quarter, which are fraudulent, illegal or violative of the Company's Code of Conduct.
- 3) That I accept responsibility for establishing and maintaining internal controls, I have evaluated the effectiveness of the internal control systems of the Company and I have disclosed to the auditors and the Audit Committee, deficiencies in the design or operation of internal controls, if any, of which I am aware and the steps that I have taken to rectify the identified deficiencies.


Rajesh P Ghatalia
CFO

Date: 14/08/2019

Place: Mumbai